GlobeNewswire: Bioblast Pharma Ltd. Contains the last 10 of 72 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:20:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/03/06/1748659/0/en/Bioblast-Announces-Effectiveness-of-Eight-to-One-Reverse-Split.html?f=22&fvtc=4&fvtv=22838Bioblast Announces Effectiveness of Eight to One Reverse Split2019-03-06T11:00:00Z<![CDATA[Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on March 6, 2019 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on March 6, 2019]]>https://www.globenewswire.com/news-release/2019/02/19/1734172/0/en/Bioblast-Pharma-Announces-Sale-of-its-Trehalose-Clinical-Development-Programs-to-Seelos-Therapeutics.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics2019-02-19T12:45:29Z<![CDATA[Tel Aviv, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. ( Nasdaq: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced the sale of its Trehalose clinical development programs (including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy (OPMD) to Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company. Under the terms of the agreement, Seelos will pay Bioblast a payment of $3.5 million in two instalments; $1.5 million payable upon closing of the sale and the other $2.0 million will be paid upon the first anniversary of the closing of the sale. Potential additional milestone payments of up to $17.0 million will be made upon completion of the clinical study and approval of a New Drug Application (NDA) by the Food and Drug Administration (FDA), as well as royalties.]]>https://www.globenewswire.com/news-release/2019/02/15/1725938/0/en/Bioblast-Pharma-Announces-Collaboration-with-Team-Sanfilippo-to-Evaluate-Trehalose-for-the-Treatment-of-Sanfilippo-Syndrome.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome2019-02-15T00:05:42Z<![CDATA[Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today announced a clinical collaboration to evaluate the safety and efficacy of Bioblast’s proprietary Trehalose solution for the treatment of patients with Sanfilippo syndrome.]]>https://www.globenewswire.com/news-release/2019/01/11/1690645/0/en/Bioblast-Pharma-Ltd-Announces-Receipt-of-Nasdaq-Notification-Regarding-Minimum-Stockholders-Equity-Non-Compliance.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance2019-01-11T21:05:00Z<![CDATA[Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).]]>https://www.globenewswire.com/news-release/2018/11/19/1654089/0/en/Bioblast-Pharma-Ltd-Announces-Entry-Into-Merger-Agreement-to-Acquire-Enlivex-Therapeutics-Ltd-to-Advance-Clinical-Stage-Immunotherapeutic-Drug-Pipeline-for-the-Treatment-of-Life-Th.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors2018-11-19T21:15:00Z<![CDATA[TEL AVIV, Israel, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq: ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the transaction, the combined company will change its name to Enlivex Therapeutics Ltd., and its trading ticker will be modified appropriately.]]>https://www.globenewswire.com/news-release/2018/07/26/1543064/0/en/Bioblast-Pharma-Ltd-Corporate-and-Management-Update.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Ltd. Corporate and Management Update2018-07-26T20:15:00Z<![CDATA[TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an organization change that affects members of the board and management.]]>https://www.globenewswire.com/news-release/2017/11/02/1173384/0/en/Bioblast-Pharma-Reports-Third-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Reports Third Quarter 2017 Financial Results2017-11-02T11:30:00Z<![CDATA[TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the third quarter ended September 30, 2017.]]>https://www.globenewswire.com/news-release/2017/09/25/1132025/0/en/Bioblast-Announces-Effectiveness-of-Five-to-One-Reverse-Split.html?f=22&fvtc=4&fvtv=22838Bioblast Announces Effectiveness of Five to One Reverse Split2017-09-25T11:00:00Z<![CDATA[Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017]]>https://www.globenewswire.com/news-release/2017/08/04/1079851/0/en/Bioblast-Pharma-Reports-Second-Quarter-2017-Financial-Results.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma Reports Second Quarter 2017 Financial Results2017-08-04T20:15:00Z<![CDATA[TEL AVIV, Israel, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the second quarter ended June 30, 2017.]]>https://www.globenewswire.com/news-release/2017/06/05/1008310/0/en/Bioblast-Pharma-to-Seek-Strategic-Alternatives-Including-Partnership-and-Merger-Opportunities.html?f=22&fvtc=4&fvtv=22838Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities2017-06-05T20:15:00Z<![CDATA[JSB-Partners Engaged to Lead the Effort]]>